PRMT5 is highly expressed in BPDCN, and its inhibition perturbs cell growth. (A) BPDCN cell lines (CAL-1 and Gen2.2) express elevated levels of MYC and PRMT5 as compared with healthy pDCs. (B) High levels of PRMT5 in de novo BPDCN mouse model (TET2 ^Δ/Δ P53 ^Δ/Δ DKO + MYC RUNX2 OE). (C) mRNA and (D) protein expression of PRMT5 after 72 hours of shRNA KD. (E) Growth of CAL-1 after PRMT5 KD, cell counts normalized to scrambled. (F) mRNA expression of PRMTs, 72 hours after shRNA KD. (G) Growth of CAL-1 after PRMT1, 4, or 7 KD, cell counts normalized to scrambled. (H) A dose-dependent decrease in CAL-1, MOLM-13, and THP-1 growth 72 hours after GSK595 treatment. Data are shown as mean ± standard error of the mean of 3 independent experiments. *P < .05; **P < .01; ***P < .001.